Biobanking Working Group Update

NMD4C is committed to strengthening the biobanking resources available to Canadian neuromuscular researchers. In rare diseases, the availability of biosamples is often limited, which hinders research into disease pathogenesis and mechanisms, and therapy development.

NMD4C is pleased to announce the addition of network collaborator Dr. Jason Karamchandani to the biobanking working group. Dr. Karamchandani is an Associate Professor in the Department of Pathology and a neuropathologist at the Montreal Neurological Institute and Hospital, who brings biobanking experience from his work with the Clinical Biospecimen Imaging and Genetic Repository (C-BIG). Dr. Karamchandani will lead the NMD4C in creating a virtual Canadian biobank, a central catalogue which will contain the neuromuscular samples available for research at the different biobanking sites across Canada.

The NMD4C biobanking group has identified eight biobanks (BDMB-MNM-MA, C-BIG, CHU Dumont Biobank, CIMS, CREATION, Neurobiobank, Pfeffer Lab Biobank) that collect and prepare a variety of samples covering a range of neuromuscular diseases. Each of these sites has provided information about what they collect, and the conditions and policies for researchers to access them. While the virtual biobank catalogue is under development, we have listed the biobanks with a summary of the NMDs covered, samples collected, associated sample data, material transfer agreements in place, context of how samples are used, and contact information on the NMD4C site, which you can access here.

If you know of any biobanks that we have missed or are involved in sample collection yourself and are interested in being listed on the NMD4C site and contributing to the virtual biobank catalogue, please let us know!

Logo_Biobank map

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.